The long-term objective of our research plan is to reduce the disproportionate effects of prostate cancer on African American men. A guiding principle of our methodology is biochemical differences exist between prostate cancers of African American and European American origin and that these differences can explain, in part, prostate cancer health disparity. In this application, we propose to use the technique of metabolomic profiling to uncover these underlying differences. Metabolomics describes the science of quantifying the levels of metabolites (e.g., small molecules) that are the byproducts of cellular metabolism. That is to say, in this kind of analysis we are measuring the biochemical entities (or metabolites) that are produced by the functional machinery of the cell. With knowledge of the identity of specific metabolites we can infer the biological processes that produced them, thus gaining insight into a cell's metabolism. To date, a metabolomic analysis of prostate cancer health disparity has not been reported. In preliminary studies, we have profiled the metabolome of prostate cancers from African-American and European American men and have identified specific racially distinct metabololites as well as biological pathways associated with each. In this proposal, we will i) validate and refine the metabolomic profile of prostate cancers from African American and European American men, ii) evaluate the role of specific biochemical pathways in prostate cancers of African American and European American men and iii) develop urine based metabolic markers for high risk prostate cancer in African American and European American men. At the conclusion of this study, we will have developed a racially derived metabolomic model for prostate cancer as well as identified candidate pathways for future drug targeting.
At present, it is not known how the prostate cancer metabolome contributes to health disparities. The information gleaned from this proposal could rapidly revolutionize current diagnostic, prognostic and therapeutic approaches by revealing the biological underpinnings of prostate cancer health disparity.
|Zhang, Li; Wang, Jianghua; Wang, Yongquan et al. (2016) MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer. Cancer Res 76:6290-6298|
|Stossi, Fabio; Dandekar, Radhika D; Bolt, Michael J et al. (2016) High throughput microscopy identifies bisphenol AP, a bisphenol A analog, as a novel AR down-regulator. Oncotarget 7:16962-74|
|Prueitt, Robyn L; Wallace, Tiffany A; Glynn, Sharon A et al. (2016) An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers. Cancer Res 76:1055-65|
|Kaushik, Akash K; Shojaie, Ali; Panzitt, Katrin et al. (2016) Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun 7:11612|
|Yang, Zi; Michailidis, George (2016) A non-negative matrix factorization method for detecting modules in heterogeneous omics multi-modal data. Bioinformatics 32:1-8|
|Shafi, Ayesha A; Putluri, Vasanta; Arnold, James M et al. (2015) Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget 6:31997-2012|
|Dasgupta, Subhamoy; Putluri, Nagireddy; Long, Weiwen et al. (2015) Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest 125:1174-88|
|Lloyd, Stacy M; Arnold, James; Sreekumar, Arun (2015) Metabolomic profiling of hormone-dependent cancers: a bird's eye view. Trends Endocrinol Metab 26:477-85|
|Jin, Feng; Bhowmik, Salil Kumar; Putluri, Vasanta et al. (2015) A Novel [(15)N] Glutamine Flux using LC-MS/MS-SRM for Determination of Nucleosides and Nucleobases. J Anal Bioanal Tech 6:|
|Zaslavsky, Alexander B; Gloeckner-Kalousek, Audrey; Adams, Mackenzie et al. (2015) Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling. Neoplasia 17:490-6|
Showing the most recent 10 out of 14 publications